GlassScriptPhysician profile
Jonathan Richard Chan
NPI 1407248552
$4,816.28
in general payments reported to CMS, 2019-2025
22 companies · $608 in 2025
The $608 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,213 · 2020: $873 · 2021: $388 · 2022: $24.39 · 2023: $348 · 2024: $362 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.18 |
| Education | $267.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,533.51 | 2019-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $851.45 | 2019-2023 | Dupixent |
| Lilly USA, LLC | $425.25 | 2019-2020 | |
| Genzyme Corporation | $361.46 | 2019-2025 | |
| Janssen Biotech, INC. | $319.62 | 2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $203.87 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $154.62 | 2023-2025 | Adbry |
| Allergan, INC. | $147.23 | 2019 | |
| Genentech USA, INC. | $121.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $100.15 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $93.68 | 2021-2024 | Absorica Ld, Winlevi, Ilumya |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Incyte Corporation | $73.65 | 2023 | Opzelura |
| Celgene Corporation | $61.62 | 2019 | |
| Pfizer INC. | $58.65 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $43.94 | 2020 | |
| Verrica Pharmaceuticals INC. | $38.69 | 2023-2025 | Ycanth |
| Kyowa Kirin, INC. | $38.24 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.20 | 2023-2025 | Jublia, Cabtreo, Siliq |
| Fidia Pharma USA INC. | $27.57 | 2024 | |
| Paratek Pharmaceuticals, INC. | $24.55 | 2021 | |
| Dermavant Sciences, INC. | $14.00 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.